Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

74.20 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Tarsus (TARS) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

XDEMVY sales hit $173.9M with 69% growth as Tarsus expands into retinal diseases.

Via The Motley Fool

Topics Earnings

Tarsus Pharmaceuticals Q2 Earnings Call Highlights ↗

August 07, 2026

Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage...

Via MarketBeat

Topics Earnings

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗

July 11, 2026

Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company...

Via MarketBeat

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗

May 06, 2026

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗

March 02, 2026

Via Chartmill

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗

February 23, 2026

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Combines High-Growth Momentum with a Favorable Technical Setup ↗

January 01, 2026

Via Chartmill

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗

July 01, 2026

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal...

Via Benzinga

Topics Law Enforcement

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

An Overview of Tarsus Pharmaceuticals's Earnings ↗

April 30, 2025

Via Benzinga

Tarsus (TARS) Q1 2026 Earnings Transcript ↗

May 06, 2026

Tarsus (TARS) Q1 2026 Earnings Transcript

Via The Motley Fool

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗

March 24, 2026

This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye diseases.

Via The Motley Fool

Topics Regulatory Compliance

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

Tarsus (TARS) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Tarsus (TARS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

What's going on in today's after hours session ↗

February 23, 2026

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout ↗

December 10, 2025

Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors.

Via Chartmill

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗

November 22, 2025

Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential.

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗

November 14, 2025

Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout.

Via Chartmill

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗

October 27, 2025

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Via The Motley Fool

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

3 Biotech Catalysts Present Major Opportunity ↗

August 25, 2025

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Via MarketBeat

Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗

August 20, 2025

Via Benzinga

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 27, 2025

Via Benzinga

6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗

May 05, 2025

Via Benzinga

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗

May 05, 2025

Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.